Sign In

Login

Password

Forgot Password ? Sign Up

デュルバルマブ (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "デュルバルマブ" in Japanese language version.

refsWebsite
Global rank Japanese rank
8astrazeneca.co.jp
low place
low place
3doi.org
2nd place
6th place
3astrazeneca.com
low place
low place
3clinicaltrials.gov
5,225th place
low place
3nih.gov
4th place
24th place
2europa.eu
68th place
425th place
2wikipedia.org
low place
low place
1drugs.com
399th place
1,603rd place
1kegg.jp
low place
2,161st place
1who.int
195th place
376th place
1fda.gov
447th place
1,043rd place
1pmda.go.jp
6,690th place
394th place
1streetinsider.com
low place
low place
1mesotheliomahelp.org
low place
low place

astrazeneca.co.jp

astrazeneca.com

clinicaltrials.gov

doi.org

  • Syn, Nicholas L; Teng, Michele W L; Mok, Tony S K; Soo, Ross A (2017). “De-novo and acquired resistance to immune checkpoint targeting”. The Lancet Oncology 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439. 
  • First line Immunotherapy for Non-Small Cell Lung Cancer. Nasser NJ, Gorenberg M, Agbarya A. Pharmaceuticals 2020, 13(11), 373 https://doi.org/10.3390/ph13110373
  • Goldman, Jonathan W. et al. (2021). “Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): Updated results from a randomised, controlled, open-label, phase 3 trial”. The Lancet Oncology 22 (1): 51–65. doi:10.1016/S1470-2045(20)30539-8. PMID 33285097. https://doi.org/10.1016/S1470-2045(20)30539-8. 

drugs.com

europa.eu

ema.europa.eu

fda.gov

kegg.jp

mesotheliomahelp.org

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Syn, Nicholas L; Teng, Michele W L; Mok, Tony S K; Soo, Ross A (2017). “De-novo and acquired resistance to immune checkpoint targeting”. The Lancet Oncology 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439. 
  • Goldman, Jonathan W. et al. (2021). “Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): Updated results from a randomised, controlled, open-label, phase 3 trial”. The Lancet Oncology 22 (1): 51–65. doi:10.1016/S1470-2045(20)30539-8. PMID 33285097. https://doi.org/10.1016/S1470-2045(20)30539-8. 

dailymed.nlm.nih.gov

pmda.go.jp

info.pmda.go.jp

streetinsider.com

who.int

wikipedia.org

en.wikipedia.org

  • 臨床試験番号 NCT02556463 研究名 "A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors" - ClinicalTrials.gov
  • 臨床試験番号 NCT03162224? 研究名 "Safety and Efficacy of MEDI0457 and Durvalumab in Patients With HPV Associated Recurrent/Metastatic Head and Neck Cancer" - ClinicalTrials.gov